# US 2008/0187929 A1 · Method for determining preeclampsia risk

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187929 A1
- Document ID: US20080187929A1
- Status: Published application
- Kind: A1
- Application number: 11/979,549
- Filed: 2007-11-05
- Published: 2008-08-07
- Earliest claimed: 2007-02-01
- Inventors: Hamutal Meiri; Marei Sammar; Renate Hillermann
- Web page: https://patentgrep.com/patent/US20080187929A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/156: Polymorphic or mutational markers
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

A method for determining the risk of a mother of a fetus to develop preeclampsia during pregnancy comprising: (a) providing a sample of genomic DNA from an individual related to the fetus; (b) analyzing the DNA for the presence of one or more mutations in the PP13 gene; and (c) determining the risk of the mother on the basis of the presence of the mutations. Also disclosed are mutated PP13 protein variants, and a kit for use in the method of the invention comprising DNA probes for specific genomic sequences of the PP13 native gene and/or mutated sequences thereof.

## Claims

### Claim 1

A method for determining the risk of a mother of a fetus to develop preeclampsia during pregnancy comprising:
(a) providing a sample of genomic DNA from an individual related to the fetus;
(b) analyzing the DNA for the presence of one or more mutations in the PP13 gene; and
(c) determining the risk of the mother on the basis of the presence of the mutations.

### Claim 2 (depends on 1)

The method of claim 1 wherein the individual related to the fetus is selected from the following:
(a) the mother of the fetus, or her mother or father;
(b) the father of the fetus or his mother or father;
(c) a sibling of the fetus or siblings of the father or of the mother of the fetus;
(d) the placenta of the pregnancy or of a twin pregnancy or the placenta from previous pregnancies of the mother; and
(e) the fetus.

### Claim 3 (depends on 1)

The method of claim 1 wherein the mutation in the PP13 gene affects one or more of the following parameters of PP13:
(a) level of expression;
(b) amino acid sequence;
(c) post-translational processing;
(d) trafficking;
(e) loss of function; and
(f) gain of function.

### Claim 4 (depends on 1)

The method of claim 1 wherein the mutation in the PP13 gene is selected from the following:
(a) frameshift mutations;
(b) chromosomal mutations;
(c) point mutations; and
(d) RNA splicing.

### Claim 5 (depends on 1)

The method of claim 1 wherein in step (c) the presence of a frameshift mutation indicates a risk to develop early onset preeclampsia.

### Claim 6 (depends on 5)

The method of claim 5 wherein the frameshift mutation is 222delT/L74W.

### Claim 7 (depends on 1)

The method of claim 1 wherein the sample of genomic DNA is provided before the mother becomes pregnant.

### Claim 8 (depends on 1)

The method of claim 1 wherein the sample of genomic DNA is provided during the pregnancy of the mother.

### Claim 9

A method for determining the risk of a pregnant woman to develop preeclampsia comprising:
(a) providing a sample of a PP13 molecule from a bodily substance of the mother;
(b) determining the structure of the PP13 molecule; and
(c) determining the risk of the woman on the basis of the structure of the PP13 molecule.

### Claim 10 (depends on 9)

The method of claim 9 wherein the bodily substance is selected from maternal blood, maternal saliva, maternal urine, amniotic fluid, umbilical cord blood, chorionic villi and placental tissue.

### Claim 11 (depends on 9)

The method of claim 9 wherein the PP13 molecule is PP13 protein, and the structure of the PP13 molecule is the molecular size or amino acid sequence of the PP13 molecule.

### Claim 12 (depends on 11)

The method of claim 11 wherein the structure of the PP13 is determined immunologically or by protein chemistry.

### Claim 13 (depends on 12)

The method of claim 12 wherein the immunological determination is made by use of specific antibodies against PP13 and/or mutated PP13.

### Claim 14 (depends on 9)

The method of claim 9 wherein the PP13 molecule is mRNA of PP13 or cDNA corresponding thereto and the structure of the PP13 molecule is the sequence of the mRNA of PP13 or cDNA corresponding thereto.

### Claim 15 (depends on 9)

The method of claim 9 wherein in step (c), the presence of a truncated PP13 due to a frameshift mutation indicates a risk to develop early onset preeclampsia.

### Claim 16 (depends on 15)

The method of claim 15 wherein the frameshift mutation is 222delT/L74W.

### Claim 17 (depends on 9)

The method of claim 9 wherein in step (c), the presence of a splice variant PP13 due to alternative splicing indicates a risk to develop late onset preeclampsia.

### Claim 18 (depends on 17)

The method of claim 17 wherein the splice variant is ΔEX-2.

### Claim 19

A mutated PP13 protein variant.

### Claim 20 (depends on 19)

The PP13 variant of claim 19 wherein the mutation is selected from the following:
(a) a frameshift mutation;
(b) a point mutation; and
(c) a mutation due to alternative splicing.

### Claim 21 (depends on 20)

The PP13 variant of claim 20 with the proviso that one or more of the following mutations is excluded:
(a) a C/A substitution [rs3764843];
(b) IVS2-22 (A/G) [rs2233706];
(c) IVS2-36 (A/G);
(d) 222delT/L74W; and
(e) ΔEX-2.

### Claim 22 (depends on 20)

The PP13 variant of claim 20 wherein the variant is selected from the group consisting of IVS2-36 (A/G), 222delT/L74W (SEQ.ID.NO:1) or ΔEX-2 (SEQ.ID.NO:2).

### Claim 23

A method for purifying a mutated PP13 protein variant in soluble form comprising:
(a) expressing the PP13 variant in a host cell;
(b) disrupting the host cell and centrifuging the cell contents;
(c) resuspending the centrifuged pellet in buffer containing a high concentration of a denaturation agent;
(d) loading the resuspended pellet on an affinity column capable of binding PP13;
(e) washing the affinity column with a gradient of the denaturation agent; and
(f) eluting the PP13 in soluble form from the column.

### Claim 24 (depends on 23)

The method of claim 23 wherein the denaturation agent is urea.

### Claim 25

A kit for use in a method for determining the risk of a woman to develop preeclampsia comprising DNA probes for specific genomic sequences of the PP.13 native gene and/or mutated sequences thereof.

### Claim 26

A kit for use in a method for determining the risk of a woman to develop preeclampsia comprising antibodies against the PP13 native sequence and/or mutated sequences thereof.

### Claim 27

A kit for use in a method for determining the risk of a woman to develop preeclampsia comprising RNA probes for specific sequences of the PP13 native mRNA and/or mutated sequences thereof.

### Claim 28

A kit for use in a method for determining the risk of a woman to develop preeclampsia comprising DNA probes for specific sequences of the PP13 cDNA and/or mutated sequences thereof.

### Claim 29

A kit for use in a method for determining the risk of a woman to develop preeclampsia comprising DNA or RNA chips comprising specific sequences of the PP13 cDNA or RNA and/or mutated sequences thereof.
